Chugai Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4519.T

Chugai Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -987.44 M

Chugai Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities is USD -987.44 M for the year ending December 31, 2023, a 11.07% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Chugai Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD -1.11 B, a -19.02% change year over year.
Chugai Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -932.95 M, a 3.10% change year over year.
Chugai Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD -962.83 M, a -56.50% change year over year.
Chugai Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD -615.22 M, a -92.62% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Tokyo Stock Exchange: 4519.T

Chugai Pharmaceutical Co., Ltd.

CEO	Dr. Osamu Okuda
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	Nihonbashi Mitsui Tower
Employees	7,604
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Key trends

Past 5 years